Genevector Completes Tens of Millions RMB in New Round of Financing to Advance AAV Gene Therapy Pipeline

VCBeat learned第一时间 that Chengdu Jinweike Biotechnology Co., Ltd. (hereinafter referred to as Jinweike, Genevector), a company dedicated to the research and development of AAV gene therapy drugs for ophthalmic diseases, neuromuscular diseases, and genetic metabolic diseases, has recently successfully completed a new round of staged financing worth tens of millions of RMB.

The investors of this round stated: "Despite the ravaging pandemic and the capital winter, we remain optimistic about the gene therapy sector. AAV gene therapy technology is one of the most cutting-edge directions in the biopharmaceutical field, and the recent global launch of multiple AAV gene therapy products demonstrates broad development prospects. Since the beginning of this year, Jinweike Biotechnology has made significant breakthroughs in production processes based on its own technical platform and solid R&D capabilities, greatly improving production efficiency and quality while reducing costs. The company's multiple product pipelines under research have also achieved phased results. We look forward to Jinweike Biotechnology accelerating the progress of its product pipelines so that more patients can access safe and effective gene therapy drugs."

Academician Weiyuquan Wei, founder and chairman of Jinweike Biotechnology, stated: "The successful completion of this round of financing is thanks to the recognition from all investors of Jinweike Biotechnology's research capabilities and team. It also gives Jinweike Biotechnology great confidence in rapidly advancing our products under development and driving corporate growth. We will accelerate our strategic layout, advance the development process of our product pipeline, and enable more patients to benefit as soon as possible."

Chengdu Jinweike Biotechnology Co., Ltd. (Jinweike, Genevector) is a company dedicated to the research and development of new AAV gene therapies for ophthalmic diseases, neuromuscular diseases, and inherited metabolic disorders. It possesses a complete R&D platform for AAV gene therapy and a rich pipeline of AAV gene therapy drugs. Its research capabilities in gene therapy drugs and AAV preparation technology are at the leading level in China.

Under the leadership of Academician Yuquan Wei and Researcher Yang Yang, Jinweike Biotechnology has built a 3,000-square-meter R&D base capable of conducting AAV gene drug research, pilot production, quality control, and clinical treatment. It has formed a highly integrated and comprehensive AAV gene therapy "technology chain." The company's AAV gene therapy products have completed clinical studies in over 100 patients, demonstrating excellent safety and efficacy data.

Jinweike Biotechnology has multiple R&D pipelines in progress, focusing on ophthalmic diseases, neuromuscular diseases, and inherited metabolic disorders. Among them, the JWK001 project for treating wet age-related macular degeneration (wAMD) has completed three batches of pilot-scale production (with batch production exceeding 10,000 doses) and is currently undergoing preclinical safety evaluation. An IND application is expected to be filed in early 2023.

Jinweike Biotechnology will leverage its robust technical platform to collaborate with leading industry partners both domestically and internationally, integrating resources to enhance the accessibility of AAV gene therapy drugs, striving to benefit a broad patient population more rapidly.